Infigratinib /kg
Phase 3Small molecule
Infigratinib /kg is one of 3 small molecule programs targeting Hypochondroplasia. It is currently in Phase 3.
1
Indications
3
Total Trials
1
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2 competitors in Hypochondroplasia
#DrugCompanyPhaseTrials
1Voxzogo
BioMarin PharmaceuticalPhase 3
Truseltiq
HHelsinn Healthcare SA
Phase 2
Infigratinib /kg
QQED Therapeutics, a BridgeBio company
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Achondroplasia2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Infigratinib /kg. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details